The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...
New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...
The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For 2025, competition and supply constraints are areas to watch.
The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...
Inquirer on MSN1h
US approves first-ever obstructive sleep apnea drugOn December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...
From childhood malaria vaccines to record-breaking solar panels to the discovery of a lost ancient city, this tumultuous year ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...
The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...
Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback